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Purpose: Endovascular therapy (EVT) has been widely performed for peripheral artery disease. However, the high
restenosis rate after EVT remains a major problem in patients on hemodialysis. Recent studies suggest that C-reactive
protein (CRP) reflects vascular wall inflammation and can predict adverse events. We evaluated the possible prognostic
values of CRP on outcomes in hemodialysis patients undergoing EVT.
Methods:A total of 234 hemodialysis patients undergoing EVT for peripheral artery disease were enrolled and followed-up
for up to 5 years. They were divided into tertiles according to serumCRP levels (lowest tertile,<1.4mg/L;middle tertile,
1.4-6.0 mg/L; highest tertile, >6.0 mg/L). We analyzed the incidence of any reintervention or above-ankle amputation
of the limb index (RAO) and any-cause death.
Results:Kaplan-Meier analysis showed that the event-free rate from the composite end point of RAO and any-cause death
for 5 years was 60.2% in the lowest tertile, 50.0% in the middle tertile, and 25.1% in the highest tertile (P < .0001). The
survival rate from any-cause death for 5 years was 81.5% in the lowest tertile, 65.2% in the middle tertile, and 59.3% in
the highest tertile (P .0078). Even after adjusting for other risk factors at baseline, preprocedural CRP levels were a
significant predictive factor for RAO and any-cause death after EVT in a multivariable Cox analysis.
Conclusions: Elevated preprocedural serum CRP levels were associated with RAO and any-cause death after EVT in
hemodialysis patients with peripheral artery disease. ( J Vasc Surg 2010;52:854-9.)Endovascular therapy (EVT), which is a less-invasive
procedure, has been widely performed to treat peripheral
artery disease (PAD).1-3 The initial success rate of EVT is
high, and using new devices is associated with better out-
comes after EVT.4-6 However, restenosis is often seen
during the follow-up phase after EVT due to a combination
of elastic recoil, negative remodeling, or hyperplasia.7,8
Thus, restenosis is a clinical limitation after EVT. Particu-
larly, patients who require maintenance hemodialysis are at
high risk for restenosis after EVT for PAD, because com-
plex lesions such as diffuse or calcified ones are frequently
seen, and neointimal growth is pronounced in these pa-
tients.9-11
C-reactive protein (CRP) reflects vascular wall inflam-
mation.12,13 A report suggests that serum CRP levels are
often increased in patients with renal dysfunction.14 In
addition, elevated CRP concentrations have been associ-
ated with adverse clinical outcomes in hemodialysis pa-
tients.15,16 However, until now, there have been limited
data on the prognostic values of serum CRP levels in any
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854reintervention or above-ankle amputation of the limb index
and any-cause death after EVT for PAD in patients on
hemodialysis. Thus, in the present study, we tested the
hypothesis that elevated CRP levels were associated with
worse clinical outcomes including any reintervention or
above-ankle amputation of the limb index and any-cause
death after EVT for PAD in patients on maintenance he-
modialysis.
METHODS
This study was approved by the Ethics Committee of
our institution. All participating patients provided written
informed consent.
Study design. Between January 2003 and January
2007, we performed a prospective observational study of
234 consecutive patients on maintenance hemodialysis
who underwent successful EVT for PAD at Nagoya Ky-
oritsu Hospital. All patients enrolled in the study had
significant PAD and underwent elective EVT for PAD at
each significant iliac or femoropopliteal obstruction. In
advance, we excluded 5 patients aged 80 years), 12 who
had cancer or active inflammation, or both, and 6 unsuc-
cessful EVT. In addition, 35 patients were treated with
bypass surgery based upon preprocedural imaging.
EVT was performed through the ipsilateral femoral
artery with an antegrade approach, and in case of obstruc-
tions close to the contralateral site, the approach to EVT
was from the ipsilateral access site. EVT was performed
after intra-arterial injection of 5000 IU heparin adminis-
tered through the sheath after arterial access. Lesions were
first treated with plain balloon dilatation. A stent was
iation
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alone, including a residual stenosis with a luminal diameter
30% or a residual flow-limiting dissection after balloon
dilatation.
All patients were administered oral aspirin (100 to 162
mg/d). In patients treated with a stent, sarpogrelate,
cilostazol, thienopyridine, or a combination, were also
prescribed. Fasting blood samples from vein were obtained
from vein between 7:00 and 8:00 AM on the day of the EVT
procedure. Serum CRP levels were measured using a latex-
enhanced high-sensitive CRP immunoassay.
The primary end point was incidence of any reinterven-
tion defined as any repeat vascular procedure or above-
ankle amputation of the limb index (RAO) and any-cause
death after EVT, according to a previous report.17 These
data were obtained from hospital medical records and
telephone interviews with patients by trained reviewers who
were blinded to the patients’ and lesions’ characteristics.
We also analyzed incidence of restenosis during the
follow-up period. Follow-up Doppler ultrasound scanning
and clinical examinations were conducted 3 months after
EVT and every 6 months thereafter. Repeat angiography
was performed if patients had an abnormal Doppler wave-
form, defined as peak systolic velocity ratio of 2.4,18
worsened clinical symptoms according to the criteria of
Fontaine classification, lowering ankle brachial pressure
index (ABPI), or worsening ulcer or gangrene, or both.
Restenosis was defined as angiographic luminal diameter
50%. These data were obtained from hospital records by
Table I. Characteristics of patients and lesions
Variable
Tertile 1
1.4 mg/L
(n  78)
Age, mean  SD, y 65  10
Male, % 62.8
Diabetes, % 69.2
Hypertension, % 62.9
Dyslipidemia, % 23.1
Smoking, % 20.5
History of CAD, % 60.2
History of stroke, % 20.5
Indication for EVT, %
Claudication 59.0
Rest pain 17.9
Ulcer/gangrene 23.1
Preoperative ABI 0.65  0.34
Medications
Aspirin, % 100
Other antiplatelet, % 83.3
Statin, % 15.4
Lesions, No. 132
Legion location, %
Iliac artery 31.1
Femoropopliteal artery 68.9
TASC classification, %
Type A  B 60.6
Type C  D 39.4
Stent use, % 72.7
ABI, Ankle-brachial index; CAD, coronary artery disease; SD, standard devexpert reviewers.Definitions. The target lesion morphology was classi-
fied by angiographic findings according to the TransAtlantic
Inter-Society Consensus (TASC) guidelines.19 Hyper-
tension was defined as a history or presence of hypertension
with systolic blood pressure160 mmHg, diastolic blood
pressure 90 mm Hg, or both, or antihypertensive treat-
ment. Diabetes mellitus (DM) was defined as a history of
DM, a fasting plasma glucose concentration126mg/dL,
a randomized plasma glucose concentration200mg/dL,
or antihyperglycemic treatment, or both. Dyslipidemia was
diagnosed if patients used any antidyslipidemic medication
or if low-density lipoprotein levels 140 mg/dL, triglyc-
eride levels150 mg/dL, or high-density lipoprotein cho-
lesterol levels40 mg/dL were found. Smoking habit was
defined as current habit or discontinued cigarette use 6
months before EVT. History of coronary artery disease
(CAD) was diagnosed if the patient had an established
history of hospitalization for CAD or if an abnormal Q
wave was present on resting electrocardiography, or both.
History of stroke was diagnosed using anatomic evidence
derived from computed tomography imaging.
Statistical analysis. All statistical analyses were per-
formed using SAS 6.10 software (SAS Institute, Cary, NC).
The analysis of variance (ANOVA) and the Fisher’s protected
least significant difference test were used for quantitative vari-
ables, and 2 test was used for categoric variables for compar-
isonof the baseline andoutcomedata amongmultiple groups.
The event-free survival rates for the primary and secondary
end point among the groups were examined with the Kaplan-
Tertile 2 Tertile 3
P
1.4-6.0 mg/L 6.0 mg/L
(n  78) (n  78)
65  10 66  10 .77
69.2 61.8 .58
56.4 64.1 .29
62.8 60.2 .94
29.6 19.2 .34
21.8 24.4 .84
66.7 62.8 .71
20.5 14.1 .49
.82
61.5 59.0 . . .
16.7 23.1 . . .
22.2 17.9 . . .
0.60  0.35 0.54  0.44 .26
100 100 .99
82.1 70.5 .10
12.8 14.1 .90
125 140
.84
29.6 27.9 . . .
70.4 72.1 . . .
.38
68.8 65.7 . . .
31.2 34.3 . . .
63.2 62.1 .14
; TASC, TransAtlantic Inter-Society Consensus.Meiermethod.Differences in survival rates among the groups
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tional-hazards models to assess univariate and multivariable
covariates. Hazard ratios (HRs) and 95% confidence intervals
(CIs) were calculated for each factor by a Cox univariate
analysis. All the prognostic valuables with P  .10 were
entered into a Cox multivariable analysis to determine inde-
pendent predictors. Differences were considered significant at
the 5% level (P .05).
RESULTS
Patients were grouped into tertiles according to the
serum CRP levels (mg/L), with the lowest tertile at 1.4,
the middle tertile at 1.4 to 6.0, and the highest tertile at
6.0. Each group included 78 patients. Table I reports the
baseline characteristics and lesion characteristics. No differ-
ences were seen in age, sex, prevalence of diabetes,
dyslipidemia, and smoking status, history of CAD and
stroke, and ankle-brachial index among the three groups.
Statins were administered to 15.4% in the lowest tertile,
12.8% in the middle tertile, and 14.1% in the highest
tertile. Lesion characteristics were also similar among the
three groups.
Follow-up was concluded on December 2007. The
mean duration of follow-up was 33 months (standard de-
viation, 21 months). Clinical follow-up data were obtained
from all patients. Ten patients (12.8%) in the lowest tertile,
17 (21.8%) in the middle tertile, and 26 (33.3%) in the
highest tertile died during the follow-up period (P 
.0090). Binary restenosis was found in 41 lesions (31.1%) in
the lowest tertile, in 50 lesions (40.0%) in themiddle tertile,
and in 74 lesions (52.9%) in the highest tertile (P .0012).
Reinterventions were required in 17 (21.8%) patients in the
lowest tertile, 24 (30.8%) in the middle tertile, and 35
(44.9%) in the highest tertile. There was no significant
difference in the rate of amputation, comprising 7 patients
(9.0%) in the lowest tertile, 14 (18.0%) in themiddle tertile,
and 14 (18.0%) in the highest tertile (P  .19).
The 5-year event-free rate from the composite end
point of RAO and any-cause death was 60.2% in the lowest
tertile, 50.0% in the middle tertile, and 25.1% in the highest
tertile by Kaplan-Meier analysis (P  .0001). RAO after
EVTwas significantly prevented in patients with lower CRP
levels as shown by the 5-year event-free rate from RAOwas
66.9% in the lowest tertile, 58.6% in the middle tertile, and
29.0% in the highest tertile (P  .0001; Table II, Fig 1).
Table II. Five-year event-free survival by Kaplan-Meier
analysis
Variable
Tertile 1 Tertile 2 Tertile 3
P
1.4 mg/L 1.4-6.0 mg/L 6.0 mg/L
(n  78) (n  78) (n  78)
Survival free from
Any reintervention 72.5 64.1 44.5 .0014
Amputation 88.7 77.3 74.8 .15
Any-cause death 81.5 65.2 59.3 .0078The survival rate from any-cause death for 5 years was81.5% in the lowest tertile, 65.2% in the middle tertile, and
59.3% in the highest tertile, respectively (P .0078; Table
II, Fig 2).
Tables III and IV report the results of Cox hazard
analysis to determine the predictive value for end points.
Serum CRP levels, presence of ulcer or gangrene, and
Fig 1. Kaplan-Meier estimates show event-free survival, with the
standard error (SE), from composite end points of any reinterven-
tion, defined as any repeat vascular procedure or above-ankle
amputation of the limb index, in patients categorized by level of
C-reactive protein into the lowest tertile (T1,1.4mg/L), middle
tertile (T2, 1.4-6.0 mg/L), and highest tertile (T3, 6.0 mg/L).
Fig 2. Kaplan-Meier estimates show event-free survival, with the
standard error (SE) from any-cause death in patients categorized
by level of C-reactive protein into the lowest tertile (T1, 1.4
mg/L), middle tertile (T2, 1.4-6.0 mg/L), and highest tertile (T3,
6.0 mg/L).TASC C or D lesions were independent predictors of RAO
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serum CRP levels, age, and presence of ulcer or gangrene.
DISCUSSION
The major findings of this study are that serum CRP
levels were associated with RAO and any-cause death after
EVT for PAD in patients on maintenance hemodialysis.
Although higher serum CRP levels are reported to predict
worse clinical outcome in hemodialysis patients,15,20 the
association between CRP levels and RAO after EVT re-
mains unclear in such patients. From this point of view, our
findings can be considered to be relatively new.
Because accelerated neointimal growth at the site of
prior intervention is pronounced in hemodialysis patients,
effects of treatments for cardiovascular disease in patients
on hemodialysis are limited.21-23 Hemodialysis patients
Table III. I. Predictive value for RAOa by Cox analysis
Variable
Univariate
HR (95% CI)
Serum CRP 1.01 (1.00-1.02)
Age 1.02 (0.99-1.04)
Male, yes/no 1.23 (0.82-1.85)
Diabetes, yes/no 1.06 (0.70-1.62)
Hypertension, yes/no 1.10 (0.71-1.69)
Dyslipidemia, yes/no 1.14 (0.72-1.78)
Smoking, yes/no 1.05 (0.62-1.78)
History of CAD, yes/no 1.17 (0.77-1.77)
History of stroke, yes/no 1.53 (0.94-2.48)
Ulcer or gangrene, yes/no 2.14 (1.34-3.43)
Statins, yes/no 0.75 (0.44-1.27)
Femoropopliteal lesion, yes/no 1.08 (0.69-1.68)
TASC type C or D, yes/no 1.90 (1.15-3.14)
Stent use, yes/no 0.70 (0.47-1.04)
CAD, Coronary artery disease; CI, confidence interval; CRP, C-reactive pr
aRAO: Any reintervention defined as any repeat vascular procedure or abov
bMultivariate model includes variable with P  .10 by univariate analysis.
Table IV. Predictive value for any-cause mortality by Cox
Variable
Univariate
HR (95% CI)
Serum CRP 1.01 (1.00-1.02)
Age 1.03 (1.01-1.09)
Male, yes/no 1.40 (0.86-2.30)
Diabetes, yes/no 1.70 (0.95-3.04)
Hypertension, yes/no 1.41 (0.83-2.41)
Dyslipidemia, yes/no 1.35 (0.80-2.28)
Smoking, yes/no 1.05 (0.55-2.01)
History of CAD, yes/no 1.15 (0.70-1.88)
History of stroke, yes/no 1.66 (0.91-3.01)
Ulcer or gangrene, yes/no 2.07 (1.13-3.76)
Statins, yes/no 0.66 (0.36-1.21)
Femoropopliteal lesion, yes/no 1.56 (0.88-2.77)
TASC type C or D, yes/no 1.17 (0.76-1.79)
Stent use, yes/no 0.96 (0.59-1.58)
CAD, Coronary artery disease; CI, confidence interval; CRP, C-reactive pr
aMultivariate model includes variable with P  .10 by univariate analysis.have a significantly lower primary patency rate, limb salvagerate, and all-cause survival rate than the general popula-
tion.11 In such situations, risk stratification to predict major
adverse events, including restenosis after EVT, is needed.
Results of this study may provide additional information to
detect high-risk patients on maintenance hemodialysis who
need EVT for PAD.
Inflammatory processes are reportedly associated with
atherosclerosis progression and plaque instability.24-26 In
addition, CRP induces atherogenesis and atherothrombo-
sis.27 A recent study reported a strong association among
malnutrition, inflammation, and atherosclerosis in chronic
renal failure, which are components of malnutrition, in-
flammation, and atherosclerosis syndrome.28-30 Thus, in-
flammation might be an important factor in treatment of
atherosclerotic lesions in hemodialysis patients. In patients
with CAD, the drug-eluting stent has been the most ex-
P
Multivariateb
PHR (95% CI)
.0059 1.01 (1.00-1.02) .0046
.14 . . . . . .
.33 . . . . . .
.78 . . . . . .
.67 . . . . . .
.57 . . . . . .
.84 . . . . . .
.46 . . . . . .
.090 1.51 (0.85-2.67) .16
.0015 2.20 (1.33-3.63) .0021
.28 . . . . . .
.74 . . . . . .
.012 2.15 (1.17-3.95) .013
.084 0.76 (0.46-1.23) .26
HR, hazard ratio; TASC, TransAtlantic Inter-Society Consensus.
e amputation of the limb index, and any-cause death.
ysis
P
Multivariatea
PHR (95% CI)
.0001 1.02 (1.01-1.03) .0001
.021 1.04 (1.01-1.07) .029
.18 . . . . . .
.075 2.04 (0.99-4.21) .053
.20 . . . . . .
.26 . . . . . .
.89 . . . . . .
.57 . . . . . .
.099 1.23 (0.59-2.56) .57
.018 2.82 (1.44-5.52) .0025
.18 . . . . . .
.13 . . . . . .
.48 . . . . . .
.89 . . . . . .
HR, hazard ratio; TASC, TransAtlantic Inter-Society Consensus.otein;
e-anklanal
otein;pected device in patients on hemodialysis, because the
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higher in hemodialysis patients than in nonhemodialysis
patients.31 However, recent reports have shown that reste-
nosis after percutaneous coronary intervention treated with
drug-eluting stent is common in patients on hemodialy-
sis.21,22,32 We have already reported that elevated prepro-
cedural serum CRP levels would predict higher major ad-
verse cardiac events, including restenosis rates, after drug-
eluting stent implantation in patients on hemodialysis.33
Thus, a higher incidence of neointimal hyperplasia is seen at
the stent site as serum CRP levels are more elevated. In the
present study, we showed that progressive atherosclerosis
after EVT was also seen in patients with higher serum CRP
levels. Our findings in the previous and present studies
might explain the association between higher CRP levels
and higher rates of adverse events in patients on mainte-
nance hemodialysis.
In the present study, patients with ulcer or gangrene
and TASC C or D lesions had higher RAO rates after EVT,
and incidence of ulcer or gangrene was an independent
predictor of RAO and any-cause death. Previous reports
have already shown that these factors are related to worse
clinical outcomes and should be considered to manage
patients on hemodialysis.19,34
There was no statistically significant difference in rates
of amputation among three groups, although there were
tendencies toward higher rates of amputation in patients
with higher serum CRP levels. It is plausible that a study
with a larger sample size may demonstrate these relation-
ships.
Study limitations. This study had several limitations.
First, the present trial was of single-center design with a
relatively small sample size. In addition, the technique used
for the EVT procedure might affect the results.
Second, we evaluated Doppler ultrasound scanning
and clinical observations from all patients. However,
follow-up angiography was not performed in all patients. It
is possible that restenosis existed if patients had normal
Doppler waveform by duplex ultrasound imaging or no
ischemic symptoms. Thus, the actual restenosis rate might
be higher.
Third, we analyzed only CRP levels as a serum inflam-
matory marker.
Fourth, we have no data on other variables related to
hemodialysis therapy, such as serum albumin, product of
serum calcium and phosphate, and intact parathyroid hor-
mone.
Fifth, effects of specific drugs, drug combinations, and
administered doses might affect the clinical outcome.
These limitations need to be considered with respect to our
study.
CONCLUSIONS
PAD is common and is an independent predictor of
all-cause mortality and cardiovascular events in patients on
maintenance hemodialysis. In the present study, we evalu-
ated a potential relationship between serum CRP levels and
clinical events after EVT in patients on hemodialysis whohad PAD. We conclude that elevated preprocedural serum
CRP levels are associated with higher rates of restenosis,
RAO, and any-cause death after EVT in such a population.
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